Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR3 | P51677 | 1/20 | 0.62 |
| ▸ | F10 | P00742 | 1/20 | 0.58 |
| ▸ | ERCC1 | P07992 | 1/20 | 0.56 |
| ▸ | ERCC4 | Q92889 | 1/20 | 0.56 |
| ▸ | LTA4H | P09960 | 1/20 | 0.55 |
| ▸ | OGA | O60502 | 1/20 | 0.54 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.54 |
| ▸ | SSTR5 | P35346 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.52 |
| ▸ | HTR2A | P28223 | 1/20 | 0.52 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.52 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.51 |
| ▸ | TCF7L2 | Q9NQB0 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4172844 | 0.89 | LTA4H (0.65) | CCR3LTA4HKMT2ACTNNB1TCF7L2 | |
| SCHEMBL28778485 | 0.80 | FAAH (0.61) | CCR3MEN1KMT2A | |
| SCHEMBL2579208 | 0.80 | KMT2A (0.74) | MEN1KMT2APTPN1 | |
| SCHEMBL30182461 | 0.80 | KMT2A (0.74) | MEN1KMT2APTPN1 | |
| SCHEMBL30182449 | 0.80 | KMT2A (0.74) | MEN1KMT2APTPN1 | |
| SCHEMBL4739633 | 0.77 | KDM4E (0.63) | ERCC1ERCC4CACNA1GHTR2A | |
| SCHEMBL26082665 | 0.76 | CCR3 (0.60) | CCR3F10ERCC1ERCC4ACKR3 | |
| SCHEMBL6994717 | 0.76 | HTR2A (0.64) | ERCC1ERCC4HTR2A | |
| SCHEMBL6154047 | 0.76 | LTA4H (0.67) | CCR3LTA4H | |
| SCHEMBL29057542 | 0.75 | OGA (0.73) | CCR3OGAMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090004185-A1 | AMINO-SUBSTITUTED QUINAZOLINE DERIVATIVES AS INHIBITORS OF BETA-CATENIN/TCF-4 PATHWAY AND CANCER TREATMENT AGENTS | WYETH (US) | 2009-01-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090004185-A1 | AMINO-SUBSTITUTED QUINAZOLINE DERIVATIVES AS INHIBITORS OF BETA-CATENIN/TCF-4 PATHWAY AND CANCER TREATMENT AGENTS | TCF4, CTNNB1, TCF7 | CCR3 3024/4885F10 4360/4885ERCC1 1945/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.